Invicta Diagnostic Limited IPO
Invicta Diagnostic Limited IPO
Invicta Diagnostic Limited IPO
₹ 272000 / 3200 Shares Shares
Minimum Investment
Invicta Diagnostic Limited IPO
Issues Price
₹80-85 per equity share
Invicta Diagnostic Limited IPO
Open Date
01 Dec 2025
Close Date
03 Dec 2025
Lot Size
1600
Min. Investment
₹ 272000
Issue Price
₹80-85
Listing Date
08 Dec 2025
Issues Size
33,08,800 shares(aggregating up to ₹28.12 crore)
Face Value
₹10 Per Equity Share
Total Shares Offered
3200 Shares
Offered To Public
3200 Shares
Invicta Diagnostic Limited IPO
Incorporated in January 2021, Invicta Diagnostic Limited offers radiology and pathology solutions. It provides pathology and radiology testing comprising imaging, radiology, pathology, and teleradiology services under the brand 'PC Diagnostics” through 7 diagnostic centres and a central laboratory across Mumbai in Maharashtra. Invicta Diagnostics Limited, trading as PC Diagnostics, is a Mumbai-based diagnostic services company specializing in integrated pathology and radiology solutions. The company follows a hub‑and‑spoke model across the Mumbai Metropolitan Region, featuring: A flagship hub offering full-spectrum pathology and advanced radiology (CT, MRI) at Thane West Three other centres - Bhayandar, Byculla, Marol - offering specialized diagnostic services Basic imaging, including X-ray and ultrasound, and sample collection were the focus of spokes at Lower Parel, Sewri, Mazgaon, and Kalwa. It offers approximately 60 routine and 487 specialized pathology tests and around 96 basic and 130 advanced radiology investigations. Invicta Diagnostics provides a comprehensive suite of diagnostic services that includes: Routine Tests: Includes CBC, lipid profiles, liver function tests (LFT), kidney function tests (KFT), and thyroid panels Specialized Tests: Molecular diagnostics, immunoassays, infectious disease markers including dengue, COVID-19, cancer markers, and genetic panels. Sample Collection Network: Invicta uses phlebotomists and collection partners to reach patients at home or through its spoke centres. The company has a network of 5 laboratory doctors, 20 radiologists, and 127 well-trained technical staff as of May 31st, 2025. The company has 105 permanent employees as of May 31, 2025.
Founded In
2021
Managing Director
Dr. Ketan Jayantilal Jain
Parent Organization
Invicta Diagnostic Limited IPO
Application for Invicta Diagnostic Limited IPO
| Apply as | Price Range | Apply Upto |
|---|---|---|
| Individual (min) | ₹80-85 | ₹2,72,000 |
| Individual(max) | ₹80-85 | ₹2,72,000 |
| SHNI(min) | ₹80-85 | ₹4,08,000 |
| SHNI(max) | ₹80-85 | ₹9,52,000 |
| BHNI(min) | ₹80-85 | ₹10,88,000 |
Apply for all eligible candidates, Invicta Diagnostic Limited IPO.
Open On12 Dec 2025
Close On16 Dec 2025
Price Range₹2061-2165
Testimonial
Genuine Review Form Statisifed Customers
KSquare’s approach to New Fund Offerings really impressed me. I finally feel confident participating in something I once thought was too complicated.
Investing used to feel intimidating, but KSquare has simplified everything. Their SIP plans offer great flexibility and peace of mind. I recommend them to all my colleagues.
KSquare offered everything I needed to invest from the UK. Their NRI Corner is efficient, clear, and built with trust.
KSquare’s New Fund Offering updates are timely and insightful. I’ve participated in two NFOs already, and the results have been quite impressive and transparent.
KSquare guided me in building a strong emergency fund. I now feel safe knowing unexpected medical or financial situations won’t disturb our family. Truly reliable and dedicated service.
KSquare’s mutual fund platform is exactly what I needed. It’s intuitive, offers diverse funds, and gives great insights. I’ve seen real growth since I started.
KSquare provided a practical solution without liquidating my investments. I’m grateful for their clarity and quick process.
I was skeptical about loans on mutual funds, but KSquare provided full clarity and fast execution. Loved the experience!
I never thought mutual fund investing could be this simple. KSquare helps me manage risk and meet financial targets effortlessly. Great for working women like me.
KSquare helped me plan my retirement with complete clarity. The SIP guidance was simple, personalised, and stress-free. I now feel financially confident about my future and family responsibilities.
FAQ's
Frequenlty Asked Question
What is the minimum amount required to start a SIP?
You can begin a SIP with as little as ₹500 per month, making it accessible for investors of all income levels.
Does KSquare provide medical emergency fund planning?
Yes, KSquare builds dedicated SIP plans focused on medical security so unexpected health expenses don’t affect regular finances.
What if I fail to repay the loan on time?
In case of default, the lender may sell pledged mutual fund units. KSquare advises timely repayment to avoid any financial impact.
Can I set up automatic investments through KSquare?
Yes, KSquare allows SIP setup, automating monthly investments to help build disciplined saving habits.
Do NFOs offer better returns than existing funds?
Not always. While some NFOs may perform well, they lack historical data. KSquare helps evaluate the potential.
What’s the minimum investment required in an NFO?
Most NFOs start with a minimum investment of ₹500 or ₹1,000. KSquare clearly shows these details for each offering.
Can I invest in mutual funds online through KSquare?
Yes, KSquare’s digital platform allows you to browse, select, and invest in mutual funds entirely online.
How do I choose the right asset allocation in NPS?
KSquare helps you select between Active and Auto choices based on your age, risk appetite, and retirement goals.
Ksquare Timeline Pvt. Ltd. is an AMFI Registered Mutual Fund Distributor having ARN No. 146262. Mutual Fund investments are subject to market risks. Please read all scheme related documents carefully before investing. This website is intended only for informational and self-help purposes and should not be considered as investment advice or return guarantee. Past performance is not indicative of future results. Terms & Conditions apply.